Bausch + Lomb (BLCO) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.34
- Estimate
- $0.22
- Surprise
- +54.7%
- Revenue (period 2026-09-30)
- $1.38B
- Score at report (before → after)
- 5.7 → 5.4/10
Revenue source: xbrl.
How the report landed
Bausch + Lomb (BLCO) beat the $0.22 estimate with adjusted EPS of $0.34 — a large 54.7% upside surprise. TrendMatrix's engine moved from Hold (5.7/10) to Sell at 5.4/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BLCO Sell at 5.4/10.
2 of the last 4 quarters beat the estimate; this quarter's +54.7% surprise compares with a +24.7% four-quarter average. Next scheduled report: 2027-02-17.
What argues against it
- Concentration risk — Product: Vision Care segment (57.0%)
- Concentration risk — Supplier: single source or limited number of sources
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $20.93
- Stop
- $19.65
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
BLCO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $7.46B
- P/E (fwd)
- 17.6
- 52-week range
- $14.44–$21.40
- Off 52-week high
- 2.2%
- RSI (14)
- 57
- Volume vs avg
- 0.31×
- Score today
- 5.4/10